Isolated posterior meningocele

Isolated posterior meningocele is a rare congenital neural tube defect in which the meninges (the protective membranes surrounding the spinal cord) protrude through a defect in the posterior vertebral arches, forming a cerebrospinal fluid-filled sac beneath the skin. Unlike myelomeningocele, this condition does not involve herniation of spinal cord tissue or neural elements into the sac, which generally results in a more favorable neurological prognosis. The defect can occur at various levels of the spine, including thoracic, lumbar, and sacral regions. Clinical presentation varies depending on the size and location of the meningocele. Many patients are identified at birth due to a visible or palpable soft mass along the midline of the back. In uncomplicated cases, neurological function may be preserved, though some patients may experience symptoms such as tethered spinal cord, urinary or bowel dysfunction, lower limb weakness, or sensory changes. Skin overlying the defect may be normal or show abnormalities such as dimpling, hair tufts, or discoloration. Hydrocephalus may occasionally be associated. The primary treatment for isolated posterior meningocele is surgical repair, which involves excision of the meningocele sac and closure of the dural and bony defects. Early surgical intervention is generally recommended to prevent complications such as infection (meningitis), rupture of the sac, or progressive neurological deterioration from tethering. Prenatal diagnosis is possible through ultrasound and maternal serum alpha-fetoprotein screening. Folic acid supplementation before and during early pregnancy is recognized as an important preventive measure for neural tube defects in general. Long-term outcomes are generally favorable when the defect is isolated and surgically corrected, though follow-up monitoring for tethered cord and urological function is recommended.

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

Common questions about Isolated posterior meningocele